HWHG(SH:600079) Xin Lang Cai Jing·2025-11-03 07:49Core Viewpoint - The company Yichang Renfu, a subsidiary of Renfu Pharmaceutical holding 80% equity, has received approval for clinical trials of the drug Prabirin extended-release tablets for the indication of postherpetic neuralgia [1] Group 1: Clinical Development - Yichang Renfu has been approved to conduct clinical trials for Prabirin extended-release tablets targeting postherpetic neuralgia [1] - This follows the earlier approval in 2023 for the same drug to treat neuropathic pain associated with diabetic peripheral neuropathy [1] - The total investment in this research project has reached approximately 55 million yuan [1] Group 2: Market Potential - The projected national sales for Prabirin formulations in 2024 are estimated to be around 690 million yuan [1] - Following the completion of clinical research, Yichang Renfu plans to apply for production and market launch [1]